US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Articles published by Telix Pharmaceuticals Limited

< Previous 1 2 3 4 Next >
News headline image
Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Files Form 20-F Registration Statement for Nasdaq ADS
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX CAH
News headline image
‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Announces Reorganisation to Deliver on Strategic Priorities
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Q2 2024 Revenue and Business Highlights, Guidance Upgrade
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Announces Launch of Proposed Initial Public Offering in the United States
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Completes TLX250-CDx (Zircaix™) BLA Submission for Kidney Cancer Imaging
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Submits NDA for New Prostate Cancer Imaging Agent
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Files Registration Statement for Proposed Initial Public Offering in the United States
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Q1 2024 Revenue and Business Update
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Appointment of Dr Darren Patti to Group Chief Operating Officer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
News headline image
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Tickers ASX:TLX
< Previous 1 2 3 4 Next >